mesothelioma/diarré

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 49 resultat

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Twenty-five patients with histologically proven malignant mesothelioma participated in a trial of imatinib mesylate (Glivec) with a starting dose of 400 mg per day taken orally, up to a maximal dose of 800 mg. No responses were observed in the patient group, while three patients showed prolonged (>6

Malignant peritoneal mesothelioma presenting with persistent high fever.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Malignant peritoneal mesothelioma (MPM) is a rare tumor that develops in the peritoneum. In this paper, we describe an extremely rare case of MPM metastasizing to the appendix in a 48-year-old female who initially presented with a persistent high fever. The woman reported a slight lower abdominal

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND We conducted a phase 2, multicenter, open-label study of erlotinib plus bevacizumab in patients with malignant pleural mesothelioma who had previously received 1 prior chemotherapy regimen. These agents have activity in non-small cell lung cancer, but their role in mesothelioma is

A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

We conducted a phase II multicenter trial to evaluate the activity of combined gemcitabine and oxaliplatin in malignant pleural mesothelioma. Twenty-five patients were recruited between May 1999 and December 2001 and received gemcitabine 1000 mg/m2 intravenously over 30 minutes and oxaliplatin 80

[Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 - A Case Report].

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Malignant mesothelioma is a rare aggressive solid tumor that is invariably incurable. A 23-year-old female patient with ascites, anemia, and high levels of ferritin and CRP was diagnosed with pleural mesothelioma by exploratory laparotomy. She remained asymptomatic, but 7 years later, she developed

Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Peritoneal mesothelioma is a rare malignancy that is seen in patients exposed to asbestos or in young women with no known exposure to asbestos. The clinical features of the disease are similar in these two groups, and include peritoneal carcinomatosis, ascites, thrombocytemia, systemic symptoms

An Unpleasant Surprise: Abdominal Presentation of Malignant Mesothelioma

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Malignant mesothelioma is an aggressive cancer associated with asbestos exposure with median survival time of 8 to 14 months following diagnosis. Given that mesothelial cells also line the peritoneum and pericardium, malignant mesothelioma can present in unusual sites and in patients with

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite,

Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

We chose to treat malignant pleural mesothelioma with a combination of docetaxel and irinotecan (CPT-11), because there have been preliminary reports that CPT-11 is active against mesothelioma, and docetaxel and CPT-11 were the most active agents in our in vitro experiments in human mesothelioma

Malignant peritoneal mesothelioma diagnosed 50 years post-radiotherapy for ovarian cancer in a patient with a history of multiple malignancies: An autopsy case.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

As the number of long-term cancer survivors is increasing, the incidence of post-irradiation malignant mesothelioma may also increase. We herein present the case of an 85-year-old female patient with a history of several surgeries for solid tumors and radiotherapy to the pelvis, who presented with

Impact of New Chemotherapeutic agents on the outcome of Egyptian patients with Advanced Malignant Pleural Mesothelioma.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Patients with malignant pleural mesothelioma (MPM) are well known to have poor response to chemotherapy. Aim of this work was to evaluate the efficacy and safety of new chemotherapeutic agents for the treatment of Egyptian MPM patients. METHODS The first study was a non-randomized, open-label trial.

[Diagnosis and treatment of 41 patients with malignant peritoneal mesothelioma].

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE To study the methods of diagnosis and treatment of malignant peritoneal mesothelioma. METHODS The clinical data of 41 patients with malignant peritoneal mesothelioma pathologically confirmed were retrospectively analyzed. RESULTS Of these 41 patients, abdominal pain and diarrhea were found

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor,

Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity of irinotecan in malignant mesothelioma (CALGB protocol 9733). METHODS Twenty-eight patients accrued between January 1998 and January 1999 received irinotecan 125 mg/m2 by intravenous

Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807). METHODS Between November 15, 2000 and August 31, 2001, 27 patients with mesothelioma were enrolled in this study. Capecitabine was

Tidigare
1
2
3
4
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning